ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,113Medicare Part D Prescriptions Filled, Including Refills

Rank: 2 out of 78

$459K Total Retail Price of All Prescriptions

Rank: 4 out of 78

332 Patients Receiving at Least One Drug in Part D
64%Patients 65 Years and Older
85% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in District of Columbia
Lower avg

Schedule Two
Controlled Substances

9% of this provider’s 332 patients filled at least one prescription for a schedule two drug, compared to an average of 3%.

Schedule Three
Controlled Substances

6% of this provider’s 332 patients filled at least one prescription for a schedule three drug, compared to an average of 3%.

Risky Drugs to Seniors

1% of this provider’s 6,343 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

23% of this provider’s prescriptions were for brand-name drugs, compared to an average of 25%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $58 among peers.

Prescriptions per Patient

27 is the average number of prescriptions (including refills) per patient, compared to an average of 19.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in District of Columbia
AMLODIPINE BESYLATE 595 497 1 2
LOSARTAN POTASSIUM 354 262 2 13
LISINOPRIL 303 214 3 1
METOPROLOL SUCCINATE 253 196 4 12
SIMVASTATIN 250 177 5 3
FUROSEMIDE 246 168 6 7
LOSARTAN-HYDROCHLOROTHIAZIDE 233 163 7 24
OMEPRAZOLE 207 137 8 6
METFORMIN HCL 199 134 9 5
LOVASTATIN 152 103 10 25
METOPROLOL TARTRATE 147 130 11 9
ATORVASTATIN CALCIUM 145 89 12 8
ACETAMINOPHEN-CODEINE 145 121 S3 12 22
RANITIDINE HCL 128 114 14 33
OXYCODONE-ACETAMINOPHEN 118 70 S2 15 49
LACTULOSE 117 98 16 70
CLOPIDOGREL 115 80 17 44
KLOR-CON M20 111 87 18 34
SERTRALINE HCL 109 58 19 27
HYDROCHLOROTHIAZIDE 105 90 20 4
CARVEDILOL 98 77 21 23
ALLOPURINOL 95 78 22 32
TRAMADOL HCL 92 51 23 28
PLAVIX 91 70 24 55
LEVETIRACETAM 89 56 25 47
DILTIAZEM 24HR ER 88 66 26 87
TRIAMTERENE-HCTZ 87 38 27 20
QUETIAPINE FUMARATE 80 45 28 46
NAMENDA 80 75 28 66
LANTUS 77 41 30 16
ATENOLOL 77 54 30 10
PRAVASTATIN SODIUM 75 57 32 11
CLONIDINE HCL 75 31 32 37
GABAPENTIN 72 63 34 14
NIFEDIPINE ER 64 22 35 26
DONEPEZIL HCL 63 63 36 36
IBUPROFEN 62 29 37 18
SINGULAIR 59 42 38 54
GLIPIZIDE 58 38 39 19
HYDRALAZINE HCL 58 35 39 48
FENTANYL 56 48 S2 41 106
NIFEDICAL XL 56 33 41 106
NOVOLOG 56 33 41 67
DIOVAN 52 44 44 29
AMITRIPTYLINE HCL 52 32 R 44 52
LISINOPRIL-HYDROCHLOROTHIAZIDE 51 40 46 21
JANTOVEN 50 43 47 74
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Dec. 4, 2007.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.